|
1 Indications And Usage Evenity Is A Sclerostin Inhibitor Indicated For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture, Defined As A History Of Osteoporotic Fracture, Or Multiple Risk Factors For Fracture; Or Patients Who Have Failed Or Are Intolerant To Other Available Osteoporosis Therapy. ( 1 ) Limitations Of Use: Limit Duration Of Use To 12 Monthly Doses. If Osteoporosis Therapy Remains Warranted, Continued Therapy With An Anti-Resorptive Agent Should Be Considered. ( 1.2 ) 1.1 Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture Evenity Is Indicated For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture, Defined As A History Of Osteoporotic Fracture, Or Multiple Risk Factors For Fracture; Or Patients Who Have Failed Or Are Intolerant To Other Available Osteoporosis Therapy. 1.2 Limitations Of Use The Anabolic Effect Of Evenity Wanes After 12 Monthly Doses Of Therapy. Therefore, The Duration Of Evenity Use Should Be Limited To 12 Monthly Doses. If Osteoporosis Therapy Remains Warranted, Continued Therapy With An Anti-Resorptive Agent Should Be Considered [See Dosage And Administration ( 2.2 ) And Clinical Studies ( 14.1 )] .
|